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Sulfamethoxazole-trimethoprim (SXT) is the drug-of-choice in Stenotropho-
monas maltophilia caused infections. There has been an increase in resistance to 
SXT of S. maltophilia over recent years. In this study 30 S. maltophilia clinical iso-
lates resistant to SXT were investigated. Antibiotic susceptibilities for ciprofl oxacin, 
moxifl oxacin, levofl oxacin, doxycycline, tigecycline, ceftazidime, colistin and chlo-
ramphenicol were determined by broth microdilution method. None of the strains 
were susceptible to ciprofl oxacin, tigecycline, ceftazidime or colistin. Only 37% of 
the isolates were susceptible to levofl oxacin or moxifl oxacin. Two isolates resistant 
to all tested antibiotic agents and two others susceptible only to doxycycline were 
further investigated: susceptibility for combinations of antibiotics was analyzed by 
checkerboard technique. According to the fractional inhibitory concentration indi-
ces calculated, moxifl oxacin plus ceftazidime combination was found to be syner-
gistic in each case. Genetic testing revealed the predominance of sul1 gene. Our 
study concluded that the range of effective antibiotic agents is even more limited in 
infections caused by SXT-resistant S. maltophilia. In these cases, in vitro synergistic 
antibiotic combinations could be potential therapeutic options.
Keywords: Stenotrophomonas maltophilia, sulfamethoxazole-trimethoprim 
resistance, antibiotic resistance, synergism
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Introduction
Stenotrophomonas maltophilia is an emerging, multidrug-resistant, Gram-
negative pathogen. After Pseudomonas aeruginosa and Acinetobacter bauman-
nii, it is the third most frequent non-fermenting Gram-negative bacteria causing 
nosocomial infections [1]. Pneumonia and bacteraemia are the most common 
clinical presentations of S. maltophilia infection, related to high mortality rate 
(14–69%) [2]. It causes infections predominantly in hospitalized and immuno-
compromised patients, but community-acquired infections have also been report-
ed. Differentiation of colonization or infection by S. maltophilia can be diffi cult, 
especially if bacteria are isolated from respiratory tract samples. Moreover, S. 
maltophilia is often isolated from polymicrobial infections, in which its role is 
diffi cult to evaluate. Due to its extended inherent antibiotic resistance (character-
ized by production of L1-, L2-β-lactamases, extended spectrum β-lactamases, 
multidrug-effl ux systems, low permeability of outer membrane, modifi ng en-
zymes and target site modifi cations), therapeutic options are strongly limited. 
The recommended fi rst-line agent is sulfamethoxazole-trimethoprim (SXT). 
 According to European Committee on Antimicrobial Susceptibility Testing 
( EUCAST), SXT is the only antibiotic agent currently that can be interpreted in 
microbiology results, based on established S. maltophilia specifi c clinical break-
points [3]. 
Resistance to SXT has been reported mainly due to modifi ed target genes 
sul1 (carried by class 1 integrons) and sul2 (carried by insertion sequence com-
mon region elements) [4, 5]. Resistance rates of SXT ranges from 2 to 10% glob-
ally; however studies from Turkey (15%), Spain (27%), Taiwan (25%) and China 
(30–48%) reported higher resistance rates [4, 6–8]. In patients suffering from 
cystic fi brosis (CF), the frequency of SXT-resistant S. maltophilia is higher (24–
84%) [2, 9–11]. Resistance level of isolates from patients with cancer and those 
treated in intensive care unit (ICU) might be also higher [4]. In case of SXT 
 resistance – as well as in cases when SXT cannot be used due to hypersensitivity 
of the patient or adverse effects in high dose therapy – alternative agents have 
to be taken into consideration. Fluoroquinolones, tetracycline derivates, colistin, 
ceftazidime and chloramphenicol can have activity against S. maltophilia, among 
few other antibiotic agents [1]. 
Aims of this study were to test the antibiotic susceptibility of S. malt-
ophilia isolates resistant to SXT, to examine the in vitro effect of few antibiotic 
combinations and to reveal the presence of the most frequent SXT-resistance cod-
ing genes.
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Materials and Methods
Our study included 30 consecutive non-duplicate S. maltophilia isolates 
collected in a fi ve-year period (2010–2014) in the Diagnostic Laboratory of Clin-
ical Microbiology, Institute of Laboratory Medicine, Semmelweis University 
(Budapest, Hungary). Isolates were identifi ed by conventional methods and 
MALDI-TOF mass spectrometry (Bruker Daltonics, Bremen) technique. Isolates 
were cultured from blood (n = 2), bronchoalveolar lavage sample (n = 8), tracheal 
aspirate (n = 3), sputum (n = 3), endotracheal tube (n = 3), rectal swab (n = 7), 
urine (n = 1), ear swab (n = 1) and throat swab (n = 2). The most of the isolates 
(n = 23) were considered clinically to be colonizer or contaminant bacteria. 
 Only seven isolates were infective as they caused lower respiratory tract infec-
tions and bacteraemia. Thirteen strains were isolated from neonates cared in neo-
natal intensive care unit (ICU), six strains from adult patients treated in ICUs.
The minimal inhibitory concentrations (MICs) of nine antibiotics were de-
termined by broth microdilution method in cation-adjusted Mueller–Hinton 
broth, according to CLSI testing conditions [12]. The antibiotics tested included 
0.5–256 mg/L SXT (Ratiopharm), 0.5–256 mg/L ciprofl oxacin (Fresenius Kabi), 
0.064–32 mg/L moxifl oxacin (Bayer Pharma), 0.064–32 mg/L levofl oxacin 
( TEVA), 1–512 mg/L colistin (Sigma-Aldrich), 0.064–32 mg/L doxycycline 
(Pfi zer), 0.064–32 mg/L tigecycline (Wyeth), 1–512 mg/L ceftazidime (Fresenius 
Kabi) and 0.5–256 mg/L chloramphenicol (Sigma-Aldrich). While EUCAST has 
S. maltophilia specifi c breakpoint only for SXT, the non-species related break-
points were applied for fl uoroquinolones, ceftazidime and tigecycline. For doxy-
cycline – due to absence of non-species related breakpoints – the epidemiological 
cut-off (ECOFF) value of S. maltophilia was applied. For colistin and chloram-
phenicol – lacking non-species related breakpoints and approved ECOFF – 
the Pseudomonas sp. specifi c colistin breakpoint and the S. maltophilia specifi c 
Clinical Laboratory Standards Institute (CLSI) chloramphenicol breakpoints 
were used, respectively. Escherichia coli ATCC 25922, Pseudomonas aerugino-
sa ATCC 27853 and Staphylococcus aureus ATCC 29213 were used as quality 
control strains, which correspond with the quality control recommendation of 
CLSI.
The 20 different antibiotic combinations tested for extremely resistant 
S. maltophilia strains were the following: a) ceftazidime plus ciprofl oxacin, mox-
ifl oxacin, levofl oxacin, doxycycline, tigecycline, colistin, SXT; b) colistin plus 
ciprofl oxacin, moxifl oxacin, levofl oxacin, doxycycline, SXT; c) tigecycline plus 
ciprofl oxacin, moxifl oxacin, levofl oxacin, colistin, SXT; d) SXT plus ciprofl oxa-
cin, moxifl oxacin, levofl oxacin. Antibiotic combinations were analysed by check-
erboard technique and in selected cases (when synergy was detected) by E-test 
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combination method and disc agar diffusion method, too [13, 14]. Fractional in-
hibitory concentration indices (FICI) were calculated following the formula 
 described in microbiology procedure guidelines [15]. The summation of FICIs of 
two antibiotics tested defi ne the effects of antimicrobial agent combinations as 
antagonistic (Σ FICI > 4), indifferent (0.5 < Σ FICI ≤ 4) or synergistic (Σ FICI ≤ 
0.5). Susceptible breakpoint indices (SBPI) were also used to interpret the re-
sults. SBPI was calculated as follows: SBPI = (susceptible breakpoint of antibi-
otic agent A / MIC of antibiotic agent A in combination) + (susceptible breakpoint 
of antibiotic agent B / MIC of antibiotic agent B in combination). An SBPI of 2 
indicates that the MIC values of the two antibiotics tested in combination are 
 either equivalent to their respective susceptible breakpoints or the MIC of one 
of the antimicrobials in a combination is less than its susceptible breakpoint. 
Greater SBPI values indicate more effective combinations [11].
Enterobacterial Repetitive Intergenic Consensus PCR (ERIC-PCR) was 
used for molecular typing of isolates, as described by Silbert et al. [16]. Isolates 
from the same ward were tested within the same PCR reaction and in the same 
gel electrophoreses run. Band patterns generated by ERIC-PCR were visually 
evaluated in the absence of appropriate software. Isolates that differed by two or 
more bands were interpreted as unrelated.
The occurrence of two frequent genes coding sulfamethoxazole resist-
ance: sul1 and sul2, and the presence of class I integron were tested by PCR as 
described previously [17].
Results
The MIC values, MIC ranges, breakpoints and interpretations are summa-
rized in Table I. All isolates tested were resistant to SXT, however, MIC values 
ranged between 8–128 mg/L. None of the isolates was susceptible to ciprofl oxa-
cin, tigecycline, ceftazidime or colistin. Only 37% of them were susceptible to 
levofl oxacin or moxifl oxacin. Interpreting isolates with MIC value under ECOFF 
as susceptible, 50% of the strains were susceptible to doxycycline. Thirteen % of 
the isolates were susceptible to chloramphenicol.
Two isolates resistant to all tested antibiotic agents and two others suscep-
tible only to doxycycline were detected. These four isolates were further investi-
gated: susceptibilities for combinations of antibiotics were tested. The calculated 
FICIs from the lowest MIC values are shown in Table II. Most of the combina-
tions had indifferent effect. Antagonistic combination was not found. Synergistic 
effect at least in one isolate was found in combinations of a) ceftazidime plus 
ciprofl oxacin, moxifl oxacin, levofl oxacin or colistin, b) colistin plus ciprofl oxa-
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cin, moxifl oxacin, levofl oxacin or doxycycline, c) tigecycline plus colistin, and 
d) SXT plus moxifl oxacin or levofl oxacin. Ceftazidime plus moxifl oxacin and 
ceftazidime plus colistin were the only combinations that showed synergistic ef-
fect on each tested isolate. Taking into consideration the peak serum levels dur-
ing antibiotic treatment (ceftazidime: 60 mg/L, ciprofl oxacin: 1.8–4.6 mg/L, 
levofl oxacin: 5.7–8.6 mg/mL, moxifl oxacin: 4.5 mg/L, colistin: 5–7.5 mg/L, SXT: 
1–2/40–60–9/105 mg/L, tigecycline: 0.63 mg/L, doxycycline: 1.5–2.1 mg/L, 
chloramphenicol: 11–18 mg/L), only the combinations of ceftazidime plus quino-
lons and colistin plus quinolones can be accepted as synergistic, in certain cases. 
Furthermore, if EUCAST susceptibility breakpoints are also taken into consid-
eration, just the MIC values of quinolones (in combination with ceftazidime: 
SBPICAZ+MXF = 2.125, SBPICAZ+LEV = 4.125) and colistin (in combination with qui-
nolons: SBPICOL+MXF = 2.125) decreased into the susceptible range, and only in one 
isolate out of the tested four ones.
Table I. Summary of MIC values and interpretations
Antimicrobial agent : 
breakpoints (mg/L)*
MIC (mg/L) % of isolates
MIC range MIC 50 MIC 90 Resistant Intermediate Susceptible
TMP-SMX : 
S≤4, R>4
8–128  32  64 100  0  0
ciprofl oxacin : 
S≤0.5, R>1
1–32   4  16  83 17  0
levofl oxacin : 
S≤1, R>2
0.5–16   2   8  20 43 37
moxifl oxacin : 
S≤0.5, R>1
0.125–8   1   4  23 40 37
doxycycline : ** 0.5–64   4  16  33 17 50
tigecycline : 
S≤0.25, R>0.5
0.5–8   2   4  97  3  0
ceftazidime : 
S≤4, R>8
16–512 128 512 100  0  0
colistin : S≤4, R>4 8–>512 128 >512 100  0  0
chloramphenicol : *** 
S≤8, R≥32
8–64  16  32  44 43 13
*Breakpoints according to EUCAST. SXT breakpoints are specifi c for S. maltophilia.
Fluoroquinolone, tigecycline and ceftazidime breakpoints are non-species related. Colistin breakpoint 
is Pseudomonas sp. specifi c.
**ECOFF of doxycycline is 8 mg/L.
***Breakpoints according to CLSI.
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Genetic testing was performed only in 27 strains out of the 30. Except of 
two isolates carrying sul2, all the others were positive for sul1. None of the strains 
contained both genes. Our study found that 7 strains (23%) carried a class 1 inte-
gron when integrase-specifi c primers were used. ERIC-PCR resulted in diverse 
patterns, but 4 identical patterns among the isolates (2 times 2 isolates, once 3 
isolates and once 9 isolates with the same band pattern) were found. Despite the 
detected clonality, isolates with the same band pattern showed different MIC 
values. All isolates were included in the fi nal evaluation of antibiotic susceptibil-
ity testing results.
Discussion
The frequency of SXT-resistant S. maltophilia isolates was found to be 2% 
in our centre [18]. Despite this low frequency and the dominantly colonizing 
presence, emergence of resistance to SXT in S. maltophilia means a real chal-
lenge. Comparing the detected MIC values to our previous results, frequency of 
antibiotic resistance was found to be higher in SXT-resistant S. maltophilia 
strains than in SXT-susceptible ones [18]. Even if the resistance rate was 20–23% 
to levofl oxacin and moxifl oxacin, these newer fl uoroquinolones mean real thera-
peutic options. Both can disrupt S. maltophilia biofi lms [1, 2]. It was demon-
strated that moxifl oxacin possesses considerable time-kill effect on SXT-resistant 
S. maltophilia [19]. The high achievable concentration of quinolones in respira-
tory tract by applying them as inhalation therapy makes these antibiotic agents 
more valuable. As it was revealed from the fi nal clinical reports retrospectively, 
4 out of the 7 infected patients were successfully treated with levofl oxacin or 
moxifl oxacin. Susceptibility for doxycycline was investigated instead of the often 
tested minocyclin, since the latter has not been distributed in Hungary. Doxycyc-
line looked to be the most effective antibiotic agent in this study, but it has to be 
emphasized that this result was based on S. maltophilia specifi c ECOFF. It is 
known that ECOFF and well-established clinical breakpoints can differ signifi -
cantly; so it has to be assessed if this agent is a real therapeutic option. However, 
our result is in concordance with a previous study, in which doxycycline was 
found to be the most active agent against SXT-resistant S. maltophilia strains 
isolated from CF patients [10]. For the interpretation of tigecycline, the lowest 
breakpoints were applied. With other breakpoints (Enterobacteriaceae specifi c 
ones) the interpreted results of tigecycline susceptibility testing would have been 
more favourable. Even if chloramphenicol is a recommended drug according to 
CLSI and 13% of SXT-resistant S. maltophilia strains were susceptible in this 
study, the severe adverse effects of this drug must be born in mind.
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Combination therapy is recommended for severe invasive infections, for 
immunocompromised patients and for empirical therapy in areas with high fre-
quency of local resistance against SXT [4]. Combinations can be more active than 
monotherapy and can reduce the risk of developing antibiotic resistance during 
treatment, but superiority of combination therapy is not proved [1]. Clinical trails 
are missing yet. Stenotrophomonas maltophilia infections are often polymicro-
bial, where the use of a combination therapy may be also advantageous [14]. 
Against biofi lm-growth S. maltophilia isolates combinations were in vitro effec-
tive, too [20]. In case of extremely drug-resistant S. maltophilia infections, com-
bination therapy can be useful (maybe the only) therapeutic alternative. Several 
studies tested in vitro antibiotic combinations on SXT-susceptible S. maltophilia 
isolates, but only few ones focused on SXT-resistant ones [21]. By different 
 methods, a lot of synergistic combinations were described; including those we 
tested [8, 11, 22–25]. According to our results, synergy is strain dependent. Cef-
tazidime and colistin can be synergistic with quinolones. The level of colistin 
or quinolones in aerosolised form can achieve 4–5 times higher concentration in 
airways than in serum during respiratory tract infections. Therefore, an antibi-
otic agent in aerosolised form in combination with an intravenous one can be 
effective, even if the FIC and SBPI do not show synergism [26].
Limitation of our study is that results gained by checkerboard method 
were confi rmed only by combined E-test method (BioMérieux) [27]. Multiple-
combination bactericidal testing and time-kill assay were not performed. How-
ever, there is no true gold standard for synergy testing. The literature suggests 
that no two synergy methods produce comparable results. Moreover, the true 
clinical relevance of synergy testing is unknown because of missing outcome-
based studies [27]. A further limitation is the number of combinations tested. 
Many other combinations, including ticarcillin-clavulanate, aztreonam, azithro-
mycin, rifampin, etc. could have been tested. We focused just on the most com-
monly used and available antibiotic agents in Hungary.
Methodically, synergic combinations detected by checkerboard method 
could be detected also by combined E-test method in our study. Maybe the E-test 
method is more practical in the daily routine in a busy diagnostic laboratory, but 
it requires very precise work. Moreover, the fi lmy growth of S. maltophilia mi-
crocolonies can make the evaluation of this test diffi cult. For antibiotic suscepti-
bility testing of S. maltophilia, disc diffusion cannot be applied (except SXT), but 
synergic effects might be detected by double disc diffusion assay [14]. Ceftazi-
dime plus levofl oxacin or moxifl oxacin synergy was detected also by this method 
in our study, but only tight inhibition zones were seen, not the typical keyhole 
shape.
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Twenty-fi ve isolates carried sul1, but only 7 were positive for class 1 inte-
gron with intI primers. It is possible that class I integrons may not have the same 
5’ and 3’ ends, as described by Hu et al. [7]. Therefore the absence of a class 1 
integron could not be confi rmed. In combination with dfrA and sul2 genes, sul1 
gene can lead to high resistance to SXT as well as multidrug resistance. While 
sul1 genes were associated with class 1 integrons and sul2 genes were found on 
plasmids, the mobilisation of sul genes is probable and likely to increase with 
SXT consumption. Ongoing resistance surveillance is needed [28].
In summary, SXT-resistant S. maltophilia strains are rarely isolated in 
our laboratory and the most of the isolates are colonizers. We concluded that 
levofl oxacin and moxifl oxacin are the most effective antibiotic agents against 
multidrug-resistant S. maltophilia. Combinations including fl uoroquinolones – 
especially moxifl oxacin – can be effective, even if the isolate was resistant to 
them. It has to be kept in mind that results of synergy testing are isolate specifi c.
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